T he first formal organizational meeting of the International Association for the Study of Lung Cancer (IASLC) was held in October of 1974 in Florence, Italy, where also the bylaws of the organization were unanimously accepted. Since then, steady growth and expansion have taken place, changing the IASLC from a tightly knitted association with a modest budget that relied on input from the members to a professional organization that arranges biannual world conferences, with more than 5000 participants at the latest one in Barcelona this year. From the beginning, the world conference has been a key event for the IASLC, providing the possibility for exchange of the most recent knowledge on the disease. In addition, these meetings included, particularly in the early years, numerous social events, and lifelong friendships were developed, with each conference establishing a special cultural atmosphere characteristic for the country it was arranged in.
Over the years, lung cancer has become a pandemic, killing more than 1.5 million people annually and displaying drastic changes in its biological pattern. The marked increase of lung cancer occurs especially in heavily populated countries, such as China and India, following the pattern of cigarette consumption, whereas the incidence is decreasing in certain Western countries. Similar to the changes in smoking habits, the disease entity has changed, with a marked increase of adenocarcinomas compared with squamous cell carcinoma, especially in women. In the same period, our knowledge of the biology of lung cancer has increased, and this has resulted in improvements in the management of lung cancer patients, with more patients receiving multidisciplinary treatment, including second-and third-line chemotherapy, which was unheard of just 5 years ago. We should not forget, however, that the 5-year overall survival remains at 15%, a figure that has been rather steady for many years.
The IASLC early recognized the need to spread the message about lung cancer by arranging or supporting meetings, workshops, symposia, and colloquiums-altogether, 58 in the period 1981 through 2001 in 21 countries covering all aspects from prevention to biology and treatment. Also, a regular contact was established to the members, initially as a newsletter, but since 1985 as a regular journal entitled Lung Cancer, which was one of the first journals to specialize on one disease. The journal is now published on a monthly basis. Again, the global aspect of the IASLC is emphasized. The recessivity of spreading information about lung cancer has also been supported by the publication of the IASLC Textbook of Lung Cancer, published first in 1999 and with a subsequent Chinese edition in 2000.
Other important aspects of IASLC activities have included the establishment of fellowships enabling young scientists to focus on research in lung cancer, and the Tokyo Declaration on Tobacco in 2000. Also, the Association plays a key role in the World Health Organization classification of lung cancer and in a new staging system together with International Union Against Cancer based on data from IASLC members all over the world.
The Association is thus developing according to the need of the members, and I hope that the IASLC will continue to play an inspiring key role in the overall battle against this dreadful disease-lung cancer.
